Is there evidence that Melanotan (including Melanotan I and Melanotan II) increases the risk of skin cancer?

Do Not Use Melanotan – It Is Unlicensed, Unsafe, and Associated with Melanoma Cases

Melanotan (both I and II) should be strongly avoided due to multiple case reports linking its use to melanoma development, combined with its unregulated status, unknown safety profile, and lack of FDA approval. While direct causation cannot be definitively proven from case reports alone, the temporal association between Melanotan use and melanoma emergence, combined with the biological plausibility of melanocyte stimulation promoting malignant transformation, creates an unacceptable risk profile.

Evidence of Cancer Risk

The most concerning evidence comes from multiple published case reports documenting melanomas occurring during or shortly after Melanotan use:

• A 2025 case report describes a 22-year-old female who developed oral mucosal malignant melanoma in the anterior maxilla after using Melanotan II nasal spray 1
• A 2014 case documents a 20-year-old woman with Fitzpatrick skin type II who developed cutaneous melanoma after a 3-4 week course of Melanotan II self-injections combined with sunbed use 2
• A 2012 case reports melanoma in situ associated with melanotan use 3
• A 2017 systematic review identified four case reports of melanomas emerging from existing moles either during or shortly after melanotan use 4

Biological Mechanisms of Concern

The mechanism by which Melanotan may increase cancer risk involves:

• Direct melanocyte stimulation via melanocortin 1 receptor (MC1R) activation, potentially promoting proliferation of both normal and dysplastic melanocytes
• Documented melanocytic changes including alterations in existing moles and emergence of new dysplastic nevi 4
• Synergistic risk when combined with UV exposure from sunbeds or sun exposure, which is common among users 2

Additional Safety Concerns Beyond Cancer

Melanotan poses multiple other serious health risks:

• Unregulated production: No quality control, unknown purity, potential contamination 5, 4
• Infectious disease transmission: Risk from needle sharing and non-sterile injection practices 5
• Unknown dosing: No standardized regimens, variable potency between batches 5
• Polypharmacy interactions: Often used alongside other performance-enhancing substances 5
• Increased UV exposure: Users frequently combine with sunbeds to enhance tanning effect 2

Clinical Recommendations

For patients who have used or are considering Melanotan:

1. Immediate cessation of all Melanotan products
2. Complete skin examination with dermatoscopy, documenting all pigmented lesions
3. Baseline photography of concerning lesions for monitoring
4. Regular surveillance every 3-6 months initially, given the unknown latency period
5. Biopsy threshold should be low for any changing or atypical lesions
6. Screen for high-risk behaviors: sunbed use, fitness/bodybuilding culture involvement 5

Important Caveats

The evidence linking Melanotan to melanoma has limitations:

• All evidence is from case reports and case series, not controlled trials
• Causation cannot be definitively established from observational data alone
• The true incidence is unknown due to underground use patterns
• Many users have multiple risk factors (fair skin, sunbed use, UV exposure) that independently increase melanoma risk 2

However, in the absence of any proven benefit and given the documented harms, the precautionary principle strongly favors complete avoidance. The fact that Melanotan is illegal in the UK and unlicensed in most countries reflects regulatory recognition of these safety concerns 1, 4.

Patient Counseling Points

When discussing with at-risk populations (young adults, fitness enthusiasts, those seeking tanning):

• Melanotan is not FDA-approved and has never completed safety testing
• Multiple health agencies have issued safety warnings 4
• The "tanning culture" in fitness communities normalizes dangerous practices 5, 4
• Safer alternatives exist: gradual sun exposure with protection, self-tanning cosmetics
• The only approved α-MSH analogue is afamelanotide, which is used only for specific medical conditions under strict supervision 4

Clinicians should maintain high suspicion for Melanotan use in young patients with:

• Unusually intense or rapid tanning
• History of fitness/bodybuilding activities
• Multiple new or changing pigmented lesions
• Upcoming sun holidays or competitions as motivating factors 5